extraskeletal myxoid chondrosarcoma
MeSH: C563195ORPHA: 2099162 Treatments Available
Overview
extraosseous chondrosarcoma that has material basis in cells derived from transformed cells that produce cartilage and is characterized by a marked abundance of extracellular mucoid (myxoid) matrix
Available Treatments (2)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| trabectedin Orphan Cold Chain | IV infusion 0.25mg/mL, 1mg/mL (1mg/4mL, 1mg/20mL vials) | FDA Approved | 8 | 21d |
| doxorubicin Cold Chain | IV injection, 2 mg/mL solution | FDA Approved, EMA Approved | 10 | 7d |
Classification & Codes
MeSH Code
C563195Orphanet Code
ORPHA:209916extraskeletal myxoid chondrosarcoma
| MeSH | C563195 |
| Orphanet | ORPHA:209916 |
| Treatments | 2 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO